Amgen Announces $200M Investment in India AI Drug R&D Center; Qilu Pharmaceutical Implicated in $1.9B Fake Invoice Scandal
Qilu Pharmaceutical
Specialty Formulations and Active Pharmaceutical Ingredients (API) Developer
Huadong Medicine
Comprehensive pharmaceutical manufacturer
XsellSmart
Stem Cell Therapy New Drug Developer
Amino Observation - Original Production by the Innovative Drug Team
Author | Huang Kai
Amgen Increases Investment in India.
On February 24, Robert Bradway, Chairman and Chief Executive Officer of Amgen, said at the inauguration ceremony of the new technology center in southern India that Amgen will invest approximately US$200 million in the center this year and plans further investment.
Qilu Pharmaceutical's Troubled Times.
On February 24, according to Interface News, the criminal judgment document with case number (2024) Wan 0181 Criminal Initial 327 showed that between December 2019 and September 2021, Chaohu Yitong Tianxia Health Consulting Co., Ltd. issued fake value-added tax invoices totaling 13,925 invoices to Qilu Pharmaceutical Co., Ltd. and its affiliated companies without any real transactions. The total amount was approximately 1.275 billion yuan, the total tax amount was 764.759 million yuan, and the combined price and tax amounted to about 1.351 billion yuan.
In the past day, what hot topics in the pharmaceutical markets at home and abroad are worth paying attention to? Let Amino take you to explore.
/ 01 /
Market Express
1) Betta Pharmaceuticals Officially Announces New R&D President
On February 24, Betta Pharmaceuticals announced that the board of directors agreed to appoint Mr. Mao Li as the President of Research and Development and Chief Medical Officer, overseeing the work of the company's new drug research and development and medical clinical research departments. The term of office will commence from the date of approval by the board of directors until the end of the current board's term.
2) Qilu Pharmaceutical Co., Ltd. Involved in Falsely Issuing Invoices Worth Nearly 1.3 Billion Yuan in Two Years
On February 24, according to Interface News, the criminal judgment document with case number (2024) Wan 0181 Criminal Initial 327 showed that between December 2019 and September 2021, Chaohu Yitong Tianxia Health Consulting Co., Ltd. issued fake value-added tax invoices totaling 13,925 invoices to Qilu Pharmaceutical Co., Ltd. and its affiliated companies without any real transactions. The total amount was approximately 1.275 billion yuan, with a tax amount of 76.4759 billion yuan, and the combined price and tax amounted to about 1.351 billion yuan.
/ 02 /
Capital Information
1) MicroPort EP 2024 Net Profit of 52.1864 Million Yuan
On February 24, MicroPort EP announced that its total operating revenue reached 413 million yuan, representing a year-on-year increase of 25.51%. The net profit attributable to the parent company's shareholders was 52.1864 million yuan, reflecting a year-on-year increase of 817.40%.
/ 03 /
Pharmaceutical News
1) Huadong Medicine's HDM1005 Injection Receives Clinical Approval
On February 24, according to the CDE official website, Huadong Medicine's HDM1005 injection received clinical approval and is intended for the treatment of obstructive sleep apnea (OSA) in adult patients with obesity or overweight.
2) XsellSmart's ALS Cell Therapy Approved for Clinical Trials in the U.S.
On February 24, XsellSmart announced that its universal iPSC-derived subtype neural progenitor cell injection (XS-228 injection) for the treatment of "ALS" has officially received approval from the U.S. FDA to initiate registration clinical trials. The product had previously been granted Orphan Drug Designation by the FDA in 2023 for treating "ALS."
/ 04 /
Instrument Tracking
1) CE Approval for Cardialen ANCHORMAN Left Atrial Appendage Occluder System and Its Delivery System
On February 21, HeartFlow Medical announced the CE approval of the ANCHORMAN Left Atrial Appendage Occluder System and its guiding system.
2) Hartkail Drug-Coated Coronary Balloon Catheter Not Registered
On February 24, according to the NMPA website, HartKel's drug-coated coronary balloon catheter was not registered.
3) Angio-Tech Peripheral Spur Balloon Dilation Catheter Not Registered
On February 24, according to the NMPA website, the registration of Angio-Tech's peripheral spinous balloon dilation catheter was not approved.
/ 05 /
Digital Healthcare Daily
1) DeepSeek + Tencent Hunyuan "Dual-Core Team" Fully Upgrades Medical Experience
Recently, Tencent Health has fully integrated DeepSeek's large model through Tencent Cloud, forming a "dual-core team" with Tencent's self-developed HunYuan large model. This integration comprehensively upgrades medical services such as intelligent triage, pre-consultation, health Q&A, smart medication guidance, symptom self-check, imaging report interpretation, and quality control. It can help over 1,000 hospitals across China quickly upgrade their intelligent applications. Additionally, it provides multi-model deployment and application solutions like bioinformatics analysis assistants and digital marketing assistants for medical institutions, health examination centers, pharmaceutical equipment enterprises, and gene sequencing companies.
/ 06 /
Overseas Pharmaceutical News
1) Pfizer Abandons a Gene Therapy
On February 22, according to Endpoints News, Pfizer confirmed in an email statement sent to the outlet that the company will terminate the development and commercialization of Beqvez, a gene therapy for hemophilia B.
2) GSK Completes Acquisition of IDRx
On February 24, GSK announced the completion of its acquisition of IDRx. The two parties reached an acquisition agreement on January 13 this year. According to the agreement, GSK will pay IDRx $1.15 billion. IDRx is a Boston-based clinical-stage biopharmaceutical company dedicated to developing precision therapies for the treatment of gastrointestinal stromal tumors (GIST). This acquisition will expand GSK's targeted treatment pipeline for gastrointestinal cancer.
3) Amgen to Invest $200 Million in Indian Plant
On February 24, Robert Bradway, Chairman and Chief Executive Officer of American pharmaceutical company Amgen, said at the inauguration ceremony of the new technology hub in southern India that Amgen will invest approximately $200 million in the center this year and plans further investment.
PS: Welcome to scan the QR code below to add the WeChat ID of Amino Jun for communication.
